Background: We evaluated AMG 386, an investigational peptibody that neutralizes the interaction between angiopoietins-1 and -2 and the Tie2 receptor, combined with cisplatin/capecitabine (CX) as first-line treatment for metastatic gastro-oesophageal cancer.
introduction
Gastric cancer is the fourth most common malignancy worldwide [1, 2] . Various chemotherapy regimens are recommended as first-line treatment for advanced disease, but outcomes are poor [3, 4] . For example, patients in a phase III study receiving 5-fluorouracil (5-FU) plus cisplatin or capecitabine plus cisplatin (CX) had median overall survival (OS) times of 9.3 and 10.5 months, respectively; CX was noninferior to 5-FU/cisplatin [5] . Therefore, recent studies have investigated the potential for improved outcomes using combinations of chemotherapy and agents that block signalling pathways believed to be important in the development and progression of gastric cancer. Specifically, these studies have assessed bevacizumab, trastuzumab, sorafenib, panitumumab, or cetuximab in the treatment of metastatic gastric cancer [6] [7] [8] [9] [10] [11] . Varying degrees of improvement in outcomes have been reported and to date, only trastuzumab has been approved (and only for patients with HER2-positive metastatic disease) [12, 13] .
The Tie2 receptor and its ligands, angiopoietin-1 (Ang1) and -2 (Ang2) are components of a signalling pathway that, in addition to the vascular endothelial growth factor (VEGF) axis, plays a key role in tumour angiogenesis [14] . Preclinical investigations have suggested that the Ang1/Ang2-Tie2 axis may be a therapeutic target in gastric cancer [15] . Several studies have demonstrated elevated expression of Ang1, Ang2, and Tie2 in gastric cancer specimens [15] [16] [17] [18] [19] , and expression of Ang1 and Ang2 has been positively correlated with tumour size and microvessel density [20] . Additionally, Ang2 expression has been associated with advanced tumour stage [17, 21] as well as lymph node and distant metastasis [21] , and Ang1 expression has been shown to be higher in poorly but not well-differentiated gastric tumours [21] .
AMG 386 (trebananib) is an intravenously administered investigational, first-in-class peptide Fc-fusion protein that inhibits angiogenesis by neutralizing the interaction of Ang1/Ang2 with the Tie2 receptor [22] . In Colo205 tumour xenograft models, dual Ang1/Ang2 blockade with AMG 386 resulted in greater tumour growth inhibition than blockade with either Ang1 or Ang2 alone [23] . In the first-in-human phase I study, AMG 386 monotherapy (0.3-30 mg/kg once weekly [QW] ) demonstrated encouraging antitumour activity and a distinct toxicity profile [13] . In subsequent phase Ib and II studies, combinations of AMG 386 10 mg/kg QW with various chemotherapy regimens were tolerable with evidence of antitumour activity [15, 16] . In patients with recurrent ovarian cancer, treatment with AMG 386 10 mg/kg QW plus paclitaxel suggested longer progression-free survival (PFS) times compared with placebo and paclitaxel (7.2 versus 4.6 months; hazard ratio [HR], 0.76; 95% CI 0.49-1.18) [24] . There was no evidence of pharmacokinetic interactions between AMG 386 and the chemotherapy regimens evaluated in these studies [24, 25] . The primary objective of the present study was to estimate the effect on PFS of AMG 386 plus CX compared with placebo plus CX in patients with metastatic gastro-oesophageal cancer. Secondary objectives included the evaluation of other efficacy measures (including objective response rate [ORR] and OS) and the toxicity of the combination. Given the lack of pharmacokinetic interactions between AMG 386 and other cytotoxic chemotherapies in previous studies [24, 25] , drug-drug interactions were not anticipated to occur when combining AMG 386 with CX. Two doses of AMG 386 were evaluated (3 and 10 mg/kg QW); both were expected to provide serum exposure above that required for antitumour activity in preclinical tumour xenograft studies [22, 26] . methods patients Eligible patients (≥18 years) had metastatic histologically or cytologically confirmed gastric, gastro-oesophageal junction, or distal oesophageal adenocarcinoma; measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.0 [27] ; Eastern Cooperative Oncology Group (ECOG) performance status ≤1; were able to swallow oral medications; and had adequate haematologic, coagulation, hepatic, cardiac, and renal function. Key exclusion criteria were prior therapy for metastatic disease; adjuvant or neoadjuvant chemotherapy, or chemoradiation within 12 months; radiation therapy ≤14 days before randomization (with recovery from related toxicities before enrolment); prior treatment with angiopoietin/Tie2 inhibitors; persistent gastric outlet obstruction, complete dysphagia, or feeding jejunostomy; history of central nervous system metastases, arterial or deep venous thromboembolism, or non-healing wound, ulcer, or fracture. Patients provided written informed consent, and study procedures were approved by an independent ethics committee/institutional review board.
study design and treatment
The study was conducted at 40 
assessments
Radiologic tumour assessment (computed tomography or magnetic resonance imaging) of the chest, abdomen, and pelvis was performed by the investigators per RECIST version 1.0 [27] at baseline and every 6 ± 1 weeks thereafter. For complete or partial responses, confirmatory scans were required ≥28 days after the initial assessment. Patients who discontinued treatment without progressive disease or withdrawal of consent were required to continue response assessments every 6 ± 1 weeks until disease progression or initiation of a new therapy.
Adverse events occurring from treatment initiation through the safety follow-up visit (30-37 days after treatment discontinuation) were recorded and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0 [22] .
statistical analysis
In this estimation study, the planned enrolment of approximately 165 patients was intended to provide estimates of treatment effect (as assessed by PFS) of AMG 386 plus CX versus placebo plus CX. The primary analysis was planned for when 113 PFS events had occurred and, with a hypothesized HR of 0.75, was anticipated to provide HRs with two-sided 80% CIs with a maximum half-width of 0.22 (0.58-0.97) for Arms A and B combined versus Arm C, and 0.25 (0.56-1.00) for Arms A or B versus C. Efficacy analyses were performed for the intent-to-treat population. For PFS and OS, HRs and CIs (80% and 95% for PFS and OS) for Arms A and B alone and combined versus Arm C were calculated using Cox regression models stratified by the randomization factors [28, 29] . Global-ordered logrank tests stratified by the randomization factors was used to assess doseresponse across treatment groups [30] . Exact binomial 2-sided 95% CIs were generated for ORR. Wilson's score method with continuity correction was used to calculate 95% CIs for differences in ORR between treatment arms [31] . The safety analysis set included patients who received ≥1 dose of study treatment. Figure 1 ). Baseline characteristics were generally balanced across treatment arms. However, there were notable differences between one or both of the AMG 386 arms and the placebo arm for the median sum of longest diameters of target lesions, patients with ≥3 sites of metastases, and mean time from diagnosis of metastatic disease to commencing treatment (Table 1) 
efficacy assessments
At the time of this primary analysis, 122 patients (71%) had had a PFS event (Table 2) . Median PFS was 4.2, 4.9, and 5.2 months in Arms A, B, and C, respectively (Table 2 ; Figure 2 ). In pairwise comparisons, the HR for PFS was 0.98 (95% CI 0.67-1.43; P = 0.92) for Arms A and B combined versus Arm C; 0.99 (95% CI 0.63-1.55; P = 0.96) for Arm A versus C; and 0.98 (95% CI 0.64-1.51; P = 0.93) for Arm B versus C. There was no evidence of a dose-response effect (P = 0.81). Eighty-one deaths occurred during the study (Arms A/B/C, n = 30/29/22). Although the data are not yet mature, median OS times at the time of analysis were 9.1, 9.4, and 12.8 months for Arms A, B, and C, respectively.
Most patients had measurable disease at baseline (Table 2) . Confirmed ORRs were 27% in Arm A, 43% in Arm B, and 35% in Arm C. Median DOR was 7.8, 4.2, and 5.4 months in Arms A, B, and C, respectively; median time to response was 5.7, 5.9, and 6.0 weeks, respectively. Although 20% of patients were unevaluable for response, it should be noted that this included patients who had a response assessment of complete or partial response, or stable disease before the first scheduled response assessment and who did not have an additional response assessment.
toxicity
The incidence of AEs (any grade) was similar across the three treatment arms. AEs occurring more frequently in the AMG 386 arms included fatigue, decreased appetite, diarrhoea, constipation, abdominal pain, and peripheral oedema, which was primarily of grade <3 (Table 3) . There was no notable difference in the patient incidence of grade 3 and grade 4 AEs between treatment arms. However, more serious AEs occurred in the AMG 386 arms relative to placebo (Arms A/B/C, 73/60/47%), including vomiting (5/21/9%), nausea (5/12/2%), anaemia (11/10/8%), and abdominal pain (11/3/2%), and more patients receiving AMG 386 than placebo discontinued all treatment (i.e. AMG 386/placebo, capecitabine, and cisplatin) because of AEs (30/26/9%). Similarly, the incidence of fatal AEs (including those associated with deaths that were attributed to disease progression) was higher in the AMG 386 arms b Two patients died; one patient was determined to be ineligible.
CX, cisplatin/capecitabine; QW, once weekly.
original articles Annals of Oncology compared with placebo (Arms A/B/C, 13/16/8%). No single specific AE accounted for the imbalances. However, the frequency of patients for whom death was not attributable to disease progression was similar across arms (5/5/4%). AEs of specific interest are summarized in Table 4 . Hypertension (no grade ≥3 events) occurred in all treatment arms but was more frequent in Arm B. The overall incidence of arterial, venous thromboembolic, and haemorrhagic events was generally similar across treatment arms. One patient in Arm A had a gastrointestinal perforation (serious grade 4 jejunal perforation). Pulmonary embolism was the most common AE to cause discontinuation of AMG 386/placebo (Arms A/B/C, 5/2/4%) and was among the most common events leading to discontinuation of chemotherapy (cisplatin, 5/2/0%; capecitabine, 4/2/0%); however, the overall incidence of pulmonary embolism was lower in the AMG 386 arms than in the placebo arm (Table 3) . Two other AEs of specific interest were noted: ascites and pleural effusion. pharmacokinetics AMG 386 displayed linear pharmacokinetic properties at both tested doses. In Arm A (10 mg/kg), median C max for AMG 386 at week 5 (243 μg/ml) was similar to that for the same dose at week 4 in the first-in-human monotherapy study (236 μg/ml) [22] . Likewise, median C min in Arm A at week 5 (14.3 μg/ml) and week 10 (14.2 μg/ml) were also similar to C min at week 4 in the AMG 386 monotherapy study (13.7 μg/ml) [22] . Median total and unbound platinum C max (end of infusion) at week 10 were similar for Arms A (total, 2850 ng/ml; unbound, 548 ng/ml), B (3540 ng/ml; 886 ng/ml), and C (3450 ng/ml; 709 ng/ml). The effect of AMG 386 on the pharmacokinetics of capecitabine and 5-FU could not be evaluated because of high data variability at week 1 and insufficient data at week 10.
In a population pharmacokinetic model, baseline creatinine clearance was a significant covariate for AMG 386 clearance. For Arms A and B combined, the 75th percentile area under the concentration-versus-time curve at steady state (AUC ss ) for AMG 386 was 8.3 mg · h/ml. original articles
Annals of Oncology pharmacodynamic biomarkers
Of eight biomarkers tested, two showed a notable pharmacodynamic response. Serum concentrations of both placental growth factor (PLGF) and soluble vascular cell adhesion molecule 1 (sVCAM-1) increased from baseline during treatment (supplementary Figure S1 , available at Annals of Oncology online), with sVCAM-1 levels showing a sustained elevation throughout the study. Although the magnitude of these increases appeared greater in the AMG 386 arms, compared with placebo, the study was not sized to evaluate this difference statistically nor was multiplicity accounted for in the evaluation of these biomarkers. The data suggest some evidence of a doseresponse for changes in sVCAM-1 and a possible additive effect of AMG 386 on the PLGF response (supplementary Figure S1 , available at Annals of Oncology online).
discussion
Numerous preclinical studies have suggested a role for the angiopoietin-1/2-Tie2 axis in the development and progression of gastric cancer [15] [16] [17] [18] [19] [20] [21] . We initiated a placebo-controlled phase II estimation study in the metastatic setting of AMG 386 plus CX, a chemotherapy regimen that has been shown to be non-inferior to 5-FU/cisplatin [5] . The study was not designed to show statistically significant differences between treatment arms; rather, it aimed at providing estimates of the treatment effect to inform the design of larger studies. Overall, the combination of AMG 386 and CX did not improve estimated PFS or ORR. There were several imbalances in baseline characteristics across the treatment arms, including tumour burden, number of metastatic sites, and time since diagnosis, and these imbalances may have contributed to the efficacy results. It should also be noted that the analyses of efficacy were not adjusted for these baseline imbalances. Exposure to AMG 386 (75th percentile AUC ss for Arms A and B combined, 8.28 mg · h/ml) was somewhat lower than previously reported in a phase II study in recurrent ovarian cancer (9.6 mg · h/ml) [32] . Median C max and C min at steady state after coadministration with capecitabine and cisplatin were dose-proportional and consistent with the first-in-human (7) 31 (53) 9 (16) 19 (36) 6 (11) Decreased appetite 17 (30) 5 (9) 31 (53) 5 (9) 23 (43) 3 (6) Diarrhoea 25 (45) 4 (7) 30 (52) 7 (12) 22 (42) 4 (8) Neutropenia 21 (38) 11 (20) 25 (43) 14 (24) 26 (49) 17 (32) Constipation 27 (48) 0 (0) 25 (43) 1 (2) 18 (34) 1 (2) Abdominal pain 17 (30) 10 (18) 23 (40) 2 (3) 9 (17) 2 (4) Anaemia 15 (27) 4 (7) 20 (34) 4 (7) 20 (38) 7 (13) Palmar-plantar erythrodysaesthesia syndrome 12 (21) 1 (2) 15 (26) 2 (3) 18 (34) 7 (13) Asthenia 8 (14) 2 (4) 13 (22) 5 (9) 18 (34) 4 (8) Peripheral oedema 7 (13) 0 (0) 17 (29) 1 (2) 3 (6) 0 (0) Upper abdominal pain 13 (23) 2 (4) 8 (14) 1 (2) 12 (23) 0 (0) Mucosal inflammation 5 (9) 2 (4) 9 (16) 2 (3) 12 (23) (14) 1 (2) 10 ( AMG 386 monotherapy study [22] . Total and unbound cisplatin levels were similar in the three treatment arms, and there was no evidence of pharmacokinetic interactions between AMG 386 and capecitabine or cisplatin. The toxicity profile for Arms A and B with respect to AE types was generally consistent with that reported in previous AMG 386 studies [22, 24, 25] . Although toxicity was manageable, a greater proportion of patients who received AMG 386 plus CX had serious or grade 5 AEs (including AEs associated with death because of disease progression) or discontinued treatment because of AEs, compared with the placebo arm. No specific toxicity accounted for this difference. Importantly, no new or unexpected toxicities emerged during the study. There was no increase in the incidence of palmarplantar erythrodysaesthesia syndrome (PPES), which is known to occur with capecitabine treatment [33] , or in mucosal inflammation in the AMG 386 plus CX arms compared with placebo plus CX ( Table 3 ). The incidence of grade ≥3 PPES was higher in the placebo arm, possibly because these patients received more cycles of CX (median, 6) than those in Arms A (median, 3.5) and B (median, 5.5). As previously reported in the AMG 386 phase II ovarian cancer study [24] , more patients in the AMG 386 arms than in the placebo arm developed peripheral oedema, an identified risk with AMG 386 treatment. In contrast to that same study, there was no increased incidence of hypokalaemia (also considered an AMG 386-specific AE) or proteinuria in the AMG 386 arms. We also noted the occurrence of ascites and pleural effusion in patients who received AMG 386 (there were no incidences in the placebo arm). Both events have also been reported in a phase II study of sunitinib in epithelial ovarian and primary peritoneal carcinoma, possibly as a result of a VEGF rebounddriven mechanism [34] . In the case of AMG 386-treated patients, it could be speculated that fluid accumulation may be related to the on-target effect of AMG 386 on lymphatic endothelial cells, which express the Tie2 receptor [35] [36] [37] .
Recently, results from the AVAGAST study of CX and bevacizumab or placebo in patients with metastatic gastric cancer have become available showing that treatment with bevacizumab and CX did not result in a significant improvement in OS (the primary end point) over placebo (12.1 versus 10.1 months; P = 0.1002) although there was an improvement in the secondary end points of PFS (6.7 versus 5.3 months; P = 0.0037) and ORR (38.0% versus 29.5%; P = 0.0121) [11] . Although patients who received 10 mg/kg of AMG 386 and CX in our study had an increase in DOR, compared with placebo, the overall results of our study and those from AVAGAST suggest that a fuller understanding of the biology of angiogenesis in gastric cancer and its contribution to disease development and progression is required to help identify patients most likely to benefit from these treatments to aid development of regimens that more effectively inhibit angiogenesis [15, 38] . In our study, an exploratory analysis of pharmacodynamic biomarkers showed that serum PLGF and sVCAM-1 increased in all three treatment arms, and there appeared to be a modest additive effect of AMG 386 compared with placebo. Although the clinical significance of these changes is unknown, there is evidence that both PLGF and VCAM-1 play roles in the development and progression of gastric cancer [39, 40] . Potentially, the observed changes in PLGF and sVCAM-1 may reflect responses of the vasculature to AMG 386 treatment and might serve as a predictive marker [41] [42] [43] [44] . However, further investigation will be required to establish such relationships.
In conclusion, in this randomized, placebo-controlled phase II estimation study, PFS and ORR were estimated to be similar with AMG 386 (10 or 3 mg/kg QW) plus CX and placebo and CX treatment among patients with metastatic gastro-oesophageal cancer. Although manageable, toxicity was greater with AMG 386 and CX compared with placebo and CX.
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